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Abstract
Background: Evaluation of the HIV Testing Week (HTW) 2015 in Amsterdam: the number of (positive) tested
persons, characteristics and testing history of the tested population, the differences in attendance per location and
the healthcare workers’ experiences and opinions concerning the HTW.
Methods: The HTW took place from 28 November till 4 December 2015. Anonymous HIV rapid testing (INSTI™
HIV1/HIV2 Ab test or Determine™ HIV-1/2 Ag/Ab test) was offered free of charge at four hospitals, 12 general
practitioner (GP) clinics, a sexually transmitted infections (STI) clinic, a laboratory, sites of a community-based
organisation, and at outreach locations. Home-based testing (OraQuick® In-Home HIV Test) was offered online. The
focus was to motivate two groups to test: men who have sex with men (MSM) and non-Western migrants.
Questionnaires regarding participant’s characteristics and HIV testing history were collected. Also healthcare workers
were asked to complete a questionnaire evaluating the HTW.
Results: In total, 1231 participants were tested. With three positive HIV tests, the detection rate was 0.3% (95%CI 0.
26–0.37). Of all participants, 24.7% (304/1231) were MSM. Respectively, 22.3% (275/1231) and 15.7% (193/1231) were
first- and second-generation migrants from a non-Western country. Altogether, 56.7% (698/1231) of participants
belonged to one of the targeted risk groups. For 32.7% (402/1231) of participants, it was the first time they received
testing, and 35.1% (432/1231) were tested more than 1 year ago. Among MSM 13.2% were tested for the first time,
among first- and second-generation non-Western migrants this percentage was significantly higher at 27.2% and
33.5% respectively (p < 0.01). The number of tested participants per location varied widely, especially between GP
clinics (range 3–63). Healthcare workers were positive about the HTW: about half (46.2%) stated they would more
readily offer an HIV test following their experience with the HTW.
Conclusions: This was the first time the Amsterdam HTW was organised on such a large scale. The majority of the
tested population belonged to one of the targeted risk groups and received testing either for the first time or for
the first time in over a year. It is important to further build upon the experiences of the HTW and offer free of
charge low-threshold HIV testing more structurally. An evaluation of cost-effectiveness is also warranted for future
editions of the HTW.
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Background
In the Netherlands an estimated 22,100 individuals are
living with HIV, of whom about 2700 (12%) are unaware
of their infection [1]. A study has demonstrated the esti-
mated percentage that is unaware among migrant
groups is even higher: 33% and 25% among HIV-
infected migrants from sub-Saharan Africa and the
Caribbean respectively [2]. Moreover, 44% of those test-
ing positive enter care late [1].
Detecting and treating HIV-infected individuals at an
early stage is an important public health challenge:
besides the prognostic benefits for the individual, there
is growing evidence that early detection and treatment is
crucial for the reduction of HIV transmission among the
population [3–5].
HIV testing is offered in different settings in the
Netherlands. At general practitioners (GP) clinics and in
hospitals HIV testing is offered on indication or request
only. Although costs of diagnostics are covered by health
insurance, people with no other healthcare expenses
have to pay the tests themselves because these costs are
set off against the obligatory deductible excess. Public
sexually transmitted infections (STI) clinics provide free-
of-charge testing for sexual transmitted infections and
HIV but only serve high-risk groups, like men who have
sex with men (MSM) and non-Western migrants.
Community-based free-of-charge HIV testing is offered
in Amsterdam by a non-governmental organization. In
addition, there are commercial providers who offer HIV
home-collection tests, and in 2014–2016 HIV self-tests
were sold in the Netherlands in a pilot programme
(www.time2test.nl). Since 2004 all pregnant women are
offered screening for HIV in prenatal care clinics.
Most national and international guidelines advocate
for a more proactive HIV testing policy for high-risk
groups [6–9]. Yet, there are barriers for its implementa-
tion. A recent study conducted in primary healthcare
settings in the Netherlands revealed that no HIV test
was performed in one-third of STI related consultations
with high-risk groups [10].
Since 2015, multiple stakeholders engaged in HIV pre-
vention and treatment joined forces on the ‘HIV Trans-
mission Elimination Amsterdam’ (H-TEAM) initiative
(www.hteam.nl), with the aim of reducing the HIV epi-
demic in Amsterdam and improving the prognosis for
people living with HIV [11]. One of the H-TEAM’s
initiatives was an HIV Testing Week (HTW) in 2015 in
Amsterdam. Anonymous HIV rapid testing was offered
free of charge at various clinical and non-clinical health-
care locations throughout the city of Amsterdam.
The goals of the HTW were to create awareness by
emphasising the importance of early testing among both
professionals and inhabitants of Amsterdam, and to nor-
malise and increase proactive HIV testing and the
detection of new HIV infections. The HTW campaign
primarily targeted two main risk-groups: MSM and non-
Western migrants.
The primary aim of this study was to evaluate whether
the HTW was an effective strategy to increase testing
and detect new infections among the targeted risk
groups. In addition, experiences with the HTW were
evaluated among the participating healthcare workers.
Methods
Test locations
The HTW took place in the week of World AIDS Day,
from 28 November till 4 December 2015.
A total of four hospitals, 12 general practitioner (GP)
clinics, the sexually transmitted infections (STI) out-
patient clinic of the Public Health Service (PHS) of
Amsterdam, a primary healthcare laboratory (SHO), and
a community-based organisation (AIDS Health Care
Foundation (AHCF)) opened their doors to anyone who
wanted to receive testing.
In addition, outreach testing was organised at different
locations. Most of the outreach activities were in the
south-eastern quarter of Amsterdam, an area with a high
proportion of non-Western migrants originating from
HIV-endemic countries (mostly Caribbean and African
countries). An extra testing site was created at the
south-eastern district’s office and a special mobile testing
bus visited various open-air markets. A home-based test-
ing pilot programme (project website www.time2test.nl)
also participated and offered free of charge HIV self-
tests during the HTW. This programme aimed to
develop and evaluate an online service that provided a
reliable HIV self-test using oral fluid People could order
the kit via the website or, using a pick-up code, at differ-
ent pick-up locations in the Netherlands. Pre- and post-
test counseling was provided online, and a telephone
number was available for personal assistance if needed.
HIV rapid tests and testing procedure
The majority of the organisations (GP clinics, STI out-
patient clinic, SHO, AHCF, AMC, and the Slotervaart
hospital) used the INSTI™ HIV1/HIV2 Rapid Antibody
test (Biolytical TM, Laboratories Inc., Richmond, BC,
Canada). The INSTI test is an HIV antibody test that
yields results within 60 s by obtaining blood with a fin-
ger prick. The other two hospitals (OLVG and DC clinic)
preferred use of the Determine™ HIV-1/2 Ag/Ab Combo
test (Alere Inc., San Diego, USA) because of their rou-
tine use of this test. The home-based self-test was an
oral HIV rapid test (OraQuick® In-Home HIV Test, Ora-
Sure Technologies, Inc., Bethlehem, USA) and could be
ordered online and picked up at the PHS of Amsterdam
as part of the Time2test project.
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In case of a positive rapid test confirmation, testing
was done at a central laboratory (of the PHS or one of
the hospitals) and when confirmed positive, a participant
was directly linked to a centre with specialised HIV care.
In Time2test project, persons who tested positive could
download a referral letter to regular health care facilities
for confirmation testing from the project website. No
data were collected from health care professionals
regarding follow-up in care for these participants.
Training of staff
In the weeks preceding the HTW, training was orga-
nised for all healthcare workers of the participating loca-
tions. During the training, healthcare workers practiced
using the INSTI-test, conducting pre- and post-test
counselling, and were briefed about the testing protocol
and questionnaires that should be offered to all
participants.
Campaign
In cooperation with the Dutch AIDS Foundation (AIDS
Fonds/SOA AIDS Nederland) a multi-media campaign
was launched in the weeks before the HTW. A website
(www.HIVtestweek.nl) was created with general infor-
mation about the HTW and contact information for all
the different testing locations. Participants could search
a map for nearby testing locations using their postal
code. Posters advertising the HTW website were placed
in 100 bus shelters throughout Amsterdam. The central
aim of the campaign was to normalise and lower the
stigma of HIV testing.
All 497 Amsterdam GP’s received an information
package including materials and the latest scientific in-
formation. A total of 25,000 flyers and 4000 posters were
distributed among 205 GP clinics, 4 hospitals, and 3
pharmacies. Also, the outreach teams of the AHCF and
the STI outpatient clinic of Amsterdam distributed
about 1000 flyers and 50 posters in gay venues in the
centre of Amsterdam and in shops, markets, community
centres, and churches in the multicultural south-eastern
quarter of Amsterdam.
Online marketing and advertising were mainly tar-
geted at the two risk groups by placing banners and
advertorials on specific websites for MSM and ethnic
minorities. Traditional media also paid attention to
the HTW: articles appeared in newspapers and several
items were broadcast on local and national radio and
television. Before the launch of the campaign a com-
munity advisory group was formed. The group con-
sisted of 12 representatives of African and Caribbean
communities who provided feedback on the campaign
and organisation of the HTW.
Evaluation HTW 2015
We evaluated the number and the characteristics of the
tested participants, the detection rate and the HTW
experience of the participating healthcareworkers. In
addition, we assessed the number of participants per
testing location in relation to promotional activities
organized by these locations.
Questionnaires participants
For evaluation purposes, all participants were asked to
complete a questionnaire regarding their demographic
background, sexual preference, HIV testing history, and
more general questions about the HTW campaign. The
questionnaires were available in English and Dutch.
In case of a positive HIV rapid test, the participant
was asked to sign an informed consent form giving re-
searchers of the PHS of Amsterdam permission to col-
lect the confirmation test results. Participants who opted
for the home-based test were asked to complete the
questionnaire when they picked up the test at the PHS.
Questionnaires healthcare workers
After the HTW, an evaluation questionnaire was sent by
mail to all testing locations (with the exception of the
PHS and the AHCF where HIV rapid testing is practised
all year round). The aim of this questionnaire was to
evaluate the opinion of the healthcare workers regarding
the HTW’s organisation and campaign, their experience
with the newly introduced rapid HIV test (the latter was
not evaluated at two hospitals where another HIV rapid
test was used), and whether or not they had initiated
extra promotional activities. At every location one
healthcare worker who was the most involved during the
HTW was requested to complete the questionnaire.
Data analysis
Descriptive statistics were used to analyse baseline char-
acteristics. Differences in testing history between risk
groups were compared using the Pearson’s chi-square
test. We considered a p-value <0.05 as statistically sig-
nificant. Analyses were performed with SPSS package
version 21 (SPSS Inc., Chicago, Illinois, USA).
The sexual preference of men was based on self-
reported sexual behaviour in the questionnaires.
The definition of Western and non-Western mi-
grants was based on the definition used by the Dutch
central agency for statistics (CBS) [12]. Also the
distinction between a first-generation migrant (person
is born in a country other than the Netherlands) and
a second-generation migrant (person is born in the
Netherlands but at least one of the parents is born in
a country other than the Netherlands) was based on
the definition of the CBS.
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A country was considered HIV-endemic when the esti-
mated HIV prevalence was higher or equal to 1.0 (based
on data of the United Nations Programs on HIV/AIDS
(UNAIDS) [13].
Results
Number of tested participants and positive rapid tests
During the HTW a total of 1231 participants were
tested: 24.6% (303/1231) at a hospital, 22.8% (281/1231)
at the STI outpatient clinic, 22.3% (275/1231) at the
AHCF and the outreach sites, 21.9% (270/1231) at the
GP clinic, and 8.1% (100/1231) through the home-based
testing project ‘Time2test’. As shown in Table 1 the
number of tested participants per location varied widely,
especially between GP clinics (range 3–63 participants).
With three positive HIV test results through rapid
testing, the overall detection rate was 0.3% (3/1131,
95%CI 0.26–0.37). Two participants gave permission for
collection of their confirmation test result: both were
confirmed positive for HIV type 1 and referred directly
to an HIV specialist for further care. The third
participant who was tested positive did not give permis-
sion for collection of the confirmation test results; this
participant tested positive with a rapid test at the
hospital where blood for confirmation tests was taken
directly.
For 10.7% (132/231) of the participants the test result
was unknown, of these, 100 were home-based test
participants and 32 were participants for whom the test
result was not recorded by the healthcare worker. The
latter group was included in the denominator of the cal-
culations for the detection rate assuming these results
were negative.
General characteristics of participants
The median age of all the participants was 33 years (IQR
26–45 years; range 16–81 years) (see Table 2). The gen-
der distribution was as follows: 58.2% (716/1231) male,
39.3% (484/1231) female, 0.2% (3/1231) transgender, and
2.3% unknown (28/1231). Of all participants, 24.7%
(304/1231) were MSM, including 13.3% homosexual
men (164/1231) and 11.4% bisexual men (140/1231).
Table 1 Number of participants and HIV positive test per test location, HIV Testing Week 2015, Amsterdam, the Netherlands
Type of location Test locations Number of participants (% of subtotal) Number of HIV positive tests (% of total)
GP clinics A 3 (1.1%) 0
B 6 (2.2%) 0
C 36 (13.3%) 0
D 30 (11.1%) 0
E 8 (3.0%) 0
F 3 (1.1%) 0
G 63 (23.3%) 0
H 11 (4.1%) 0
I 54 (20.0%) 0
J 10 (3.7%) 0
K 18 (6.7%) 0
L 28 (10.4%) 1/28 (3.6%)
Subtotal GP clinics 270 (21.9%) 1/270 (0.4%)
Hospitals AMC 42 (13.9%) 0
Slotervaart hospital 35 (11.6%) 0
OLVG 206 (68.0%) 1/206 (0.5%)
DC Clinic 20 (6.6%) 0
Subtotal hospitals 303 (24.6%) 1/303 (0.3%)
Outreach PHS outreach 28 (10.2%) 0
Aids Healthcare Foundation 247 (89.8%) 0
Subtotal outreach 275 (22.3%) 0
Municipal Health Service PHS STI outpatient clinic 281 (22.8%) 1/281 (0.4%)
Laboratory SHO 2 (0.2%) 0
Home-based test Time2test 100 (8.1%) Unknown
Total 1231 (100%) 3/1131a (0.3%)
aof 100 participants who did the home-based test (Time2test) the test results were unknown
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In total, 40.4% (497/1231) of the participants were na-
tive Dutch, 22.3% (275/1231) were first-generation mi-
grants from a non-Western country, 8.2% (101/1231)
were first-generation migrants from a Western country,
15.7% (193/1231) were second-generation migrants from
a non-Western country, 2.1% (26/1231) were second-
generation migrants from a Western country, and of
11.3% (139/1231) data were lacking concerning country
of origin. Of the non-Western migrants, 60.5% (283/
468) originated from an HIV endemic country.
Altogether, 56.7% (698/1231) of the participants
belonged to one of the HTW targeted risk groups (MSM
and/or first- or second-generation migrants from a non-
Western country).
Testing history
For 32.7% (402/1231) of the participants, it was the
first time they were tested for HIV, 25.2% (310/1231)
had been tested less than a year ago, 35.1% (432/
1231) were tested more than 1 year ago, 1.4% (17/
1231) had been previously tested but information
about the moment of testing was unknown, and of
the remaining 5.7% (70/1231) it was unknown
whether they had ever been tested.
Testing history differed by risk group: 13.2% (40/304)
of the MSM had never been tested for HIV, of the first-
and second-generation non-Western migrants (and not
MSM) a significantly higher percentage of 27.2% (61/
224) and 33.5% (57/170), respectively, had never been
tested for HIV (p < 0.01).
Opinions and experiences of participating healthcare
workers
In total, healthcare workers of 14 of the 17 test locations
that were sent an evaluation questionnaire (12 GP
clinics, four hospitals, and one primary healthcare la-
boratory) responded.
Overall the healthcare workers that completed the
questionnaire were positive about the organisation and
campaign of the HTW; an average rating of 8 was given
(on a scale of 0 to 10). A majority (85.7%) were willing
(sure to most likely) to participate in the next HTW.
The healthcare workers of the locations that used
the INSTI test (n = 12) were positive about the ease
of use of the test (an average rating of 7.8) and about
the whole procedure related to a direct result (an
average rating of 8.6). A majority (84.6%) of the
health care workers was positive about the idea of
using the INSTI test more regularly in practice. Al-
most half of the healthcare workers (46.2%) would
more readily offer their patients an HIV test (sure to
most likely) after their experience with the HTW.
The extent to which healthcare workers of the loca-
tions had initiated activities to attract more partici-
pants varied between the locations. The three GP
clinics with the highest attendance (36 to 51 partici-
pants) had posted information on their websites and/
or had invited their patients by email., whereas the
GP clinics with a lower attendance (3–30 participants)
did not report extra promotional activitites.
Discussion
This was the first time the Amsterdam HTW was
organised on such a large scale. Although the number
of tested persons varied widely among the different
test locations, we reached a total of 1231 persons.
More than half (56.7%) of the tested population
belonged to one of the targeted risk groups. A sub-
stantial new group of people was reached for HIV
testing by the HTW: about one-third of the tested
participants received HIV testing for the first time
and about one-third for the first time in over a year.
Three persons were newly diagnosed with HIV
through rapid testing (0.3%), who all tested for HIV
Table 2 General characteristics of the participants of the HIV
Testing Week 2015, Amsterdam, The Netherlands
General characteristics (N = 1231) Years (IQRa) n/N (%)
Median age 33.0 (26–45)
Gender
Male 716 (58.2%)
Female 484 (39.3%)
Transgender 3 (0.2%)
Unknown 28 (2.3%)
Sexual orientation menb
Men who have sex with men: 304 (24.7%)
Homosexual men 164 (13.3%)
Bisexual men 140 (11.4%)
Heterosexual men 400 (32.5%)
Unknown 12 (1.0%)
Ethnicity
Dutch native 497 (40.4%)
First-generationcmigrant from a non-Westernd
country
275 (22.3%)
Second-generatione migrant from a non-Western
country
193 (15.7%)
First-generation migrant from a Western country 101 (8.2%)
Second-generation migrant from a Western
country
26 (2.1%)
Unknown 139 (11.3%)
ainterquartile range
b% of total study population
cfirst-generation migrant = participant is born in a country other than
the Netherlands
daccording to a country list of the Dutch central agency of statistics (CBS)
esecond-generation migrant = at least one of the parents of the paricipant is
born in a country other than the Netherlands
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for the first time. In general, the participating health-
care workers were positive about the HTW. The ma-
jority of healthcare workers that used the rapid test
indicated to be willing to use this HIV test more
regularly in practice and about half of this group
would offer an HIV test more readily in the future.
Although the absolute number of three positive HIV
test results is not high, the detection rate of 0.3% was as
high as the annual detection rate among high-risk visi-
tors of the STI outpatient clinic in Amsterdam [14]. It is
comparable with testing weeks in other countries. In
England, a national HTW was organised at various
outpatient and emergency departments in 2014 and a
detection rate of 0.12% was found [15]. In the USA, a
National HIV Testing Day (NHTD) is organised every
year and in 2010 a detection rate of 0.7% was reported
in the week around the NHTD [16]. Yet, measuring the
success of the HTW by comparing the detection rates
between countries is not that simple: in England and the
Netherlands the detection rates were based on very
small numbers of detected infections (in England
there were also three newly diagnosed). Moreover, the
adult background prevalence of HIV in the USA
(0.4%–0.9%) is higher than in England and the
Netherlands (0.2%) [17].
One of the aims of the HTW was to increase aware-
ness concerning HIV testing among professionals. It is
not clear whether the HTW influenced healthcare
workers’ HIV testing behaviour, but they did provide
positive feedback regarding the intention to perform
more proactive HIV testing in their daily routine.
A recent analysis of the Centers for Disease Control and
Prevention (CDC) revealed a significant increase in HIV
testing and new HIV diagnoses around the NHTD in the
USA [18]. For future HTW’s in Amsterdam we also plan to
evaluate whether the HTW will have an enduring effect on
provider-initiated testing. In addition, the impact on aware-
ness concerning HIV testing among the population and the
cost-effectiveness of the HTW need further investigation.
Community involvement of different cultural ethnic
organisations played an important role in the organisa-
tion and campaign of this HTW. As shown in the re-
sults, about one-third of the tested non-Western
migrants had never been tested. Available research
suggests that migrants originating from non-Western
countries have a higher vulnerability for HIV and are
not using HIV testing facilities optimally, namely testing
late [19]. Among migrants there are more barriers to
HIV testing, such as a lower risk perception, lack of gen-
eral knowledge about HIV, fear of the consequences of a
positive HIV result, negative social norms, and costs of
HIV tests [20–25]. Moreover, structural preconditions
like the availability of affordable low-threshold testing
in neighbourhoods with a high concentration of
migrants are essential [19]. There is still much to improve
concerning low-threshold testing in these kinds of neigh-
bourhoods in Amsterdam, like the multicultural south-
eastern district. Besides provider-initiated testing at GP
clinics and the STI outpatient clinic, community-based
testing needs more attention. The HTW was an impulse
to enhance pro-active HIV testing among migrants. After
the HTW the STI outpatient clinic intensified STI testing
among migrants by expanding the STI/sexual health care
in a satellite clinic in the south-eastern district of
Amsterdam.
The HTW not only has to be seen as an intervention
in itself, but also as a catalyst for new strategies which
could accelerate HIV testing, create awareness, and
lower barriers for testing among specific risk groups and
professionals. A new strategy to lower barriers for test-
ing could include offering HIV self-tests online or at
pharmacies. An evaluation of a recent trial using self-
tests (Time2test) that was offered during the HTW
demonstrated it was successful in reaching first-time
and infrequent testers [26]. Other studies investigating
home-based and in-pharmacy testing in different
European countries and the USA also show promising
results [27–30]. In countries like France, the USA,
and the United Kingdom reliable self-tests are now
approved to be sold structurally at pharmacies or on-
line [31, 32]. Unfortunately the Dutch government
still does not allow professional parties to offer reli-
able HIV self-tests online.
Conclusions
In conclusion, the HTW was an important additional
step in creating awareness and lowering the barriers for
proactive HIV testing. The results showed that the ma-
jority of the tested population belonged to one of the
targeted risk groups and that a new group of people was
reached that had never been tested. Now it is time to
further build upon the experiences of the HTW and
have free of charge low-threshold HIV testing offered
more structurally by healthcare professionals and in
community-based settings.
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